Norway· NO-ID_0D37CF5A-A8DE-4C6A-9A41-9B3AA8812D97
Besremi
A ropeginterferon alfa-2b product containing ropeginterferon alfa-2b, registered in Norway by AOP Orphan Pharmaceuticals AG. The same ATC class is registered in 12 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Ropeginterferon alfa-2b is registered in 12 of 19 countries.
Countries holding a registration under ATC L03AB15 (ropeginterferon alfa-2b), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 8 of them publish a price we can compare per daily dose
Ropeginterferon alfa-2b · ATC L03AB15
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FEST (Norway)- Active substance
- Ropeginterferon Alfa-2b
- Manufacturer
- AOP Orphan Pharmaceuticals AG
- Country
- Norway (NO)
- ATC code
- L03AB15
- ATC class
- Ropeginterferon alfa-2b
- Defined daily dose
- 18 mcg, P
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
1 priced- no_merkevare_idID_0D37CF5A-A8DE-4C6A-9A41-9B3AA8812D97
- no_varenummer4955970.5NOK 30621.5
- gtin9007653001058
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ropeginterferon alfa-2b in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesBESREMiPharmaEssentia USA
- FinlandBesremiOrifarm Oy
- CzechiaBESREMIAOP Orphan Pharmaceuticals GmbH, Wien
- IrelandBesremi 250 micogram/0.5 ml Solution for injection in pre-filled penAop Orphan Pharmaceuticals GmbH
- SwitzerlandBesremi
- PolandBesremiAOP Orphan Pharmaceuticals GmbH
- SwedenBesremi 250 mikrogram/0,5 ml Injektionsvätska, lösning i förfylld injektionspennaAop Orphan Pharmaceuticals GmbH
- BelgiumBesremi 250 µg/0.5 mlAOP Orphan Pharmaceuticals
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Besremi
- Liechtenstein · Besremi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/2325721b-64f2-4e0f-b274-3222daade12f GET /v1/drugs/2325721b-64f2-4e0f-b274-3222daade12f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Injeksjonsvæske, oppløsning i ferdigfylt penn",
"source": "fest",
"status": "A",
"atc_name": "Ropeginterferon alfa-2b",
"merkevare_id": "ID_0D37CF5A-A8DE-4C6A-9A41-9B3AA8812D97",
"name_form_strength": "Besremi inj, oppl 250 mikrog/penn",
"prescription_group": "C"
}See everything about ropeginterferon alfa-2b.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.